- Home
- CTHR vs HEPA Comparison
CTHR vs HEPA Comparison
Compare CTHR & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTHR
- HEPA
- Stock Information
- Founded
- CTHR 1995
- HEPA 2013
- Country
- CTHR United States
- HEPA United States
- Employees
- CTHR N/A
- HEPA N/A
- Industry
- CTHR Consumer Specialties
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- CTHR Consumer Discretionary
- HEPA Health Care
- Exchange
- CTHR Nasdaq
- HEPA Nasdaq
- Market Cap
- CTHR 4.1M
- HEPA 4.7M
- IPO Year
- CTHR 1997
- HEPA N/A
- Fundamental
- Price
- CTHR $1.30
- HEPA $0.68
- Analyst Decision
- CTHR
- HEPA Hold
- Analyst Count
- CTHR 0
- HEPA 1
- Target Price
- CTHR N/A
- HEPA N/A
- AVG Volume (30 Days)
- CTHR 19.6K
- HEPA 39.0K
- Earning Date
- CTHR 11-26-2024
- HEPA 11-26-2024
- Dividend Yield
- CTHR N/A
- HEPA N/A
- EPS Growth
- CTHR N/A
- HEPA N/A
- EPS
- CTHR N/A
- HEPA N/A
- Revenue
- CTHR $23,684,860.00
- HEPA N/A
- Revenue This Year
- CTHR $31.82
- HEPA N/A
- Revenue Next Year
- CTHR N/A
- HEPA N/A
- P/E Ratio
- CTHR N/A
- HEPA N/A
- Revenue Growth
- CTHR N/A
- HEPA N/A
- 52 Week Low
- CTHR $1.18
- HEPA $0.55
- 52 Week High
- CTHR $4.90
- HEPA $4.47
- Technical
- Relative Strength Index (RSI)
- CTHR 40.56
- HEPA 52.88
- Support Level
- CTHR $1.32
- HEPA $0.60
- Resistance Level
- CTHR $1.52
- HEPA $0.68
- Average True Range (ATR)
- CTHR 0.09
- HEPA 0.05
- MACD
- CTHR 0.02
- HEPA 0.00
- Stochastic Oscillator
- CTHR 35.56
- HEPA 87.80
About CTHR Charles & Colvard Ltd
Charles & Colvard Ltd manufactures, markets, and distributes finished jewellery which also includes moissanite gemstone in the jewellery market. The company sells jewels through two operating segments namely Online Channels segment and Traditional segment. It generates maximum revenue from the Online Channels segment. Online Channels segment which consists of e-commerce outlets including charlesandcolvard.com, moissaniteoutlet.com, third-party online marketplaces, drop-ship retail, and other pure-play, exclusively e-commerce outlets.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.